References
- Benson C A, Kaplan J E, Masur H, Pau A, Holmes K K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005; 40: S131
- Cheson B D. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431–2448
- Laurenti L, Piccioni P, Piccirillo N, Sora F, Chiusolo P, Garzia M, et al. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients. Leuk Lymphoma 2004; 45: 2063–2070
- Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
- Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
- Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single vs. double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
- Goldschmidt H, Sonneveld P, Cremer F W, van der Holt B, Westveer P, Breitkreutz I, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 2003; 82: 654–659
- Dykewicz C A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139–144
- Harousseau J L. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005; 17: 93–98
- Douek D C, Vescio R A, Betts M R, Brenchley J M, Hill B J, Zhang L, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875–1881
- Rosinski S L, McNiece I K, Shpall E J, Clough N, Russell P, Blunk B, et al. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant 2005; 27: 27
- Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C, et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197